Pharmaceutical - Financial, Immunologicals, MAGE-A3


IVO portfolio company Circassia plans to float on LSE


The UK’s Imperial Innovations Group says that its largest portfolio company Circassia, has today announced…

Allergy TherapeuticsCircassiaFinancialImmunologicalsPharmaceutical

ALK’s 2013 annual report shows profit down but sales steady

ALK’s 2013 annual report shows profit down but sales steady


Denmark-based allergy specialist ALK Abello (ALKB: DC) has released its annual report for 2013 recording…

ALK AbelloDenmarkFinancialImmunologicalsPharmaceutical

Medigene’s buy of Trianta is “lucrative move” say analysts


Medigene’s 4 million euro ($5.5 million) purchase of fellow German company Trianta Immunotherapies…

FinancialImmunologicalsMedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesUSA

Merck’s Allergopharma to invest 40 million euros in production facility

Merck’s Allergopharma to invest 40 million euros in production facility


Germany’s Merck KGaA has broken ground on a new production facility for its Allergopharma unit in Reinbek…

AllergopharmaFinancialImmunologicalsMerck KGaAPharmaceuticalProduction

Stallergenes report growth in third quarter results


French allergy specialists Stallergenes has released its third quarter results showing revenue growth…


Pfizer legacy company agrees near half billion dollar settlement with DoJ


Wyeth Pharmaceuticals, a US pharma rival acquired by US behemoth Pfizer (NYSE:PFE) in 2009, has agreed…

FinancialImmunologicalsLegalMarkets & MarketingNorth AmericaPfizerPharmaceuticalRapamuneWyeth

AstraZeneca plans more job cuts; inks $240M-plus deal with Moderna; expands alliance with Karolinska Institutet


Anglo-Swedish drug major AstraZeneca (LSE: AZN), ahead of its Investor Day briefing in New York later…

AstraZenecaCardio-vascularFinancialImmunologicalsInflammatory diseasesLicensingModerna TherapeuticsOncologyPharmaceuticalResearch

Merck & Co submits ragweed AIT BLA to the FDA


US pharma giant Merck & Co (NYSE: MRK) has submitted a Biologics License Application (BLA) to the US…

ALK AbelloFinancialImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

News briefs from Genmab/Kyowa Hakko; Alimera/Quintiles; Novo Nordisk; Astellas; Sandoz


Denmark-based Genmab (GEN: CO) and Japan's Kyowa Hakko (TYO: 4151) K have entered into a license agreement…

Alimera SciencesAstellas PharmaFinancialGenericsGenmabIluvienImmunologicalsKyowa HakkoLicensingMarkets & MarketingNovartisNovo NordiskOphthalmicsPharmaceuticalQuintilesRegulationSandoztacrolimus

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval


The UK's Vectura Group (LSE: VEC) confirmed that its partner, Swiss drug giant Novartis (NOVN: VX) has…

CerticanEuropeFinancialImmunologicalsNovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonaryVectura

Ablynx earns milestone from Merck Serono


Belgium’s Ablynx (Euronext Brussels: ABLX) says it will earn a 1 million-euro ($1.3 million) from…

AblynxBiotechnologyFinancialImmunologicalsMerck KGaAMerck SeronoPharmaceuticalResearch

Back to top